Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences
06 janv. 2022 07h00 HE
|
Synlogic, Inc.
- On track to initiate Phase 3 for treatment of phenylketonuria (PKU) in H2 2022 - - Additional milestones include multiple clinical read-outs across programs including enteric hyperoxaluria and...